This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts initiated coverage on several companies with bullish ratings. BMO Capital initiated ACADIA Pharmaceuticals (ACAD) with an Outperform rating and a $31 price target. Mizuho initiated Grab Holdings (GRAB) with an Outperform rating and a $5 price target. Redburn Atlantic initiated Vertex Pharmaceuticals (VRTX) with a Buy rating and a $545 price target. Stephens & Co. initiated Hologic (HOLX) with an Overweight rating and an $87 price target. Oppenheimer initiated Kyndryl Holdings (KD) with an Outperform rating and a $33 price target.
June 27, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital initiated coverage on ACADIA Pharmaceuticals with an Outperform rating and a $31 price target. Shares fell 0.6% to $15.50.
The Outperform rating and high price target suggest a positive outlook, likely boosting investor confidence despite the recent share price drop.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Mizuho initiated coverage on Grab Holdings with an Outperform rating and a $5 price target. Shares fell 0.3% to $3.51.
The Outperform rating and price target indicate a positive outlook, which could attract investors despite the slight share price decline.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Stephens & Co. initiated coverage on Hologic with an Overweight rating and an $87 price target. Shares gained 0.9% to $72.27.
The Overweight rating and price target indicate a positive outlook, likely to boost investor confidence and share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Oppenheimer initiated coverage on Kyndryl Holdings with an Outperform rating and a $33 price target. Shares fell 1% to $25.28.
The Outperform rating and price target suggest a positive outlook, which could attract investors despite the recent share price drop.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Redburn Atlantic initiated coverage on Vertex Pharmaceuticals with a Buy rating and a $545 price target. Shares rose 0.1% to $474.00.
The Buy rating and high price target suggest strong growth potential, likely to positively impact investor sentiment and share price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 100